Centaurus

Rosuvastatin 20 mg superior to atorvastatin 80 mg in reducing apoB/apoA-1 at 1 month in patients with non-ST elevation ACS - CENTAURUS Study

Background

Data has shown that apoB/apoA1 ratio provides a better risk estimate for acute myocardial infarction than the low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol ratio or the total cholesterol/HDL ratio.

Objective

To assess the efficacy of rosuvastatin 20 mg vs. atorvastatin 80 mg in reducing apolipoprotein B/ apolipoprotein A-1 (ApoB/ApoA-1) ratio at 3 months.

Study Design

Randomized, double-blind, parallel-group trial
Patients randomized to receive either rosuvastatin 20 mg or atorvastatin 80 mg

Patient Profile

Patients diagnosed with non-ST elevation acute coronary syndrome.
753 patients were included in intention-to-treat analysis.

Study Endpoints

Percentage change in apoB/apoA1 ratio at 1 month and 3 months.

Results

ApoB/apoA-1 ratio reduction was significantly greater with rosuvastatin 20 mg as compared to atorvastatin 80 mg at 1 month similar in both groups at 3 months (Table).

Conclusion

In patients with non-ST elevation acute coronary syndrome, rosuvastatin 20 mg decreased apoB/apoA-1 ratio at 1 month more than atorvastatin 80 mg and no difference was found at 3 months.

Arch Cardiovasc Dis 2010; 103: 160-9